Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Intervalo de año de publicación
1.
Front Mol Neurosci ; 16: 1087745, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36818652

RESUMEN

History is full of women who made enormous contributions to science. While there is little to no imbalance at the early career stage, a decreasing proportion of women is found as seniority increases. In the multiple sclerosis (MS) field, 44% of first authors and only 35% of senior authors were female. So, in this review, we highlight ground-breaking research done by women in the field of MS, focusing mostly on their work as principal investigators. MS is an autoimmune disorder of the central nervous system (CNS), with evident paradigm shifts in the understating of its pathophysiology. It is known that the immune system becomes overactivated and attacks myelin sheath surrounding axons. The resulting demyelination disrupts the communication signals to and from the CNS, which causes unpredictable symptoms, depending on the neurons that are affected. Classically, MS was reported to cause mostly physical and motor disabilities. However, it is now recognized that cognitive impairment affects more than 50% of the MS patients. Another shifting paradigm was the involvement of gray matter in MS pathology, formerly considered to be a white matter disease. Additionally, the identification of different T cell immune subsets and the mechanisms underlying the involvement of B cells and peripheral macrophages provided a better understanding of the immunopathophysiological processes present in MS. Relevantly, the gut-brain axis, recognized as a bi-directional communication system between the CNS and the gut, was found to be crucial in MS. Indeed, gut microbiota influences not only different susceptibilities to MS pathology, but it can also be modulated in order to positively act in MS course. Also, after the identification of the first microRNA in 1993, the role of microRNAs has been investigated in MS, either as potential biomarkers or therapeutic agents. Finally, concerning MS therapeutical approaches, remyelination-based studies have arisen on the spotlight aiming to repair myelin loss/neuronal connectivity. Altogether, here we emphasize the new insights of remarkable women that have voiced the impact of cognitive impairment, white and gray matter pathology, immune response, and that of the CNS-peripheral interplay on MS diagnosis, progression, and/or therapy efficacy, leading to huge breakthroughs in the MS field.

2.
Cells ; 10(11)2021 11 13.
Artículo en Inglés | MEDLINE | ID: mdl-34831386

RESUMEN

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is characterized by the presence of demyelinated regions with accumulated myelin lipid debris. Importantly, to allow effective remyelination, such debris must be cleared by microglia. Therefore, the study of microglial activity with sensitive tools is of great interest to better monitor the MS clinical course. Using a boronic acid-based (BASHY) fluorophore, specific for nonpolar lipid aggregates, we aimed to address BASHY's ability to label nonpolar myelin debris and image myelin clearance in the context of demyelination. Demyelinated ex vivo organotypic cultures (OCSCs) and primary microglia cells were immunostained to evaluate BASHY's co-localization with myelin debris and also to evaluate BASHY's specificity for phagocytosing cells. Additionally, mice induced with experimental autoimmune encephalomyelitis (EAE) were injected with BASHY and posteriorly analyzed to evaluate BASHY+ microglia within demyelinated lesions. Indeed, in our in vitro and ex vivo studies, we showed a significant increase in BASHY labeling in demyelinated OCSCs, mostly co-localized with Iba1-expressing amoeboid/phagocytic microglia. Most importantly, BASHY's presence was also found within demyelinated areas of EAE mice, essentially co-localizing with lesion-associated Iba1+ cells, evidencing BASHY's potential for the in vivo bioimaging of myelin clearance and myelin-carrying microglia in regions of active demyelination.


Asunto(s)
Ácidos Borónicos/química , Colorantes/química , Enfermedades Desmielinizantes/patología , Diagnóstico por Imagen , Colorantes Fluorescentes/química , Microglía/patología , Vaina de Mielina/patología , Fagocitosis , Animales , Línea Celular , Endocitosis , Fluorescencia , Humanos , Macrófagos , Ratones Endogámicos C57BL , Ratas Wistar
3.
Angew Chem Int Ed Engl ; 60(19): 10850-10857, 2021 05 03.
Artículo en Inglés | MEDLINE | ID: mdl-33513271

RESUMEN

Widely used reagents in the peptide functionalization toolbox, Michael acceptors and N-hydroxysuccinimide (NHS) activated esters, are combined in NHS-activated acrylamides for efficient chemoselective amino-sulfhydryl stapling on native peptides and proteins. NHS-activated acrylamides allow for a fast functionalization of N-terminal cysteines (k2 =1.54±0.18×103  M-1 s-1 ) under dilute aqueous conditions, enabling selectivity over other nucleophilic amino acids. Additionally, the versatility of these new bioconjugation handles was demonstrated in the cross-linking of in-chain or C-terminal cysteines with nearby lysine residues. NHS-activated acrylamides are compatible with the use of other cysteine selective reagents, allowing for orthogonal dual-modifications. This strategy was successfully applied to the late-stage functionalization of peptides and proteins with a PEG unit, fluorescent probe, and cytotoxic agent. The level of molecular control offered by NHS-activated acrylamides is expected to promote amino-sulfhydryl stapling technology as a powerful strategy to design functional bioconjugates.

4.
Int J Mol Sci ; 21(17)2020 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-32825077

RESUMEN

Multiple sclerosis (MS) is the most common autoimmune and demyelinating disease of the central nervous system (CNS), characterized, in the majority of cases, by initial relapses that later evolve into progressive neurodegeneration, severely impacting patients' motor and cognitive functions. Despite the availability of immunomodulatory therapies effective to reduce relapse rate and slow disease progression, they all failed to restore CNS myelin that is necessary for MS full recovery. Microglia are the primary inflammatory cells present in MS lesions, therefore strongly contributing to demyelination and lesion extension. Thus, many microglial-based therapeutic strategies have been focused on the suppression of microglial pro-inflammatory phenotype and neurodegenerative state to reduce disease severity. On the other hand, the contribution of myelin phagocytosis advocating the neuroprotective role of microglia in MS has been less explored. Indeed, despite the presence of functional oligodendrocyte precursor cells (OPCs), within lesioned areas, MS plaques fail to remyelinate as a result of the over-accumulation of myelin-toxic debris that must be cleared away by microglia. Dysregulation of this process has been associated with the impaired neuronal recovery and deficient remyelination. In line with this, here we provide a comprehensive review of microglial myelin phagocytosis and its involvement in MS development and repair. Alongside, we discuss the potential of phagocytic-mediated therapeutic approaches and encourage their modulation as a novel and rational approach to ameliorate MS-associated pathology.


Asunto(s)
Microglía/inmunología , Esclerosis Múltiple/terapia , Fagocitosis , Animales , Humanos , Inmunoterapia/métodos , Esclerosis Múltiple/inmunología
5.
Chemistry ; 26(62): 14064-14069, 2020 Nov 06.
Artículo en Inglés | MEDLINE | ID: mdl-32449571

RESUMEN

Boronic acid-derived salicylidenehydrazone complex (BASHY) dyes with a polymethine backbone were designed to yield efficient red-emitting and two-photon absorbing fluorophores that can be used as markers for astrocytes. The dyes are chemically stable in aqueous solution and do not undergo photodecomposition. Their photophysical properties can be electronically fine-tuned and thereby adapted to potentially different imaging situations and requirements.


Asunto(s)
Ácidos Borónicos , Técnicas Citológicas , Colorantes Fluorescentes , Quinolinas , Coloración y Etiquetado , Astrocitos/citología , Ácidos Borónicos/química , Colorantes Fluorescentes/química , Fotones , Quinolinas/química , Agua/química
6.
Rev. colomb. radiol ; 14(3): 1392-1397, sept. 2003. ilus, tab
Artículo en Español | LILACS | ID: lil-420998

RESUMEN

Introducción: la displasia fibrosa ósea es una entidad benigna que se caracteriza por la incapacidad para producir hueso lamelar maduro. Dependiendo de la proporción que exista entre hueso y tejido fibroso la apariencia radiológica es variable. Objetivo: establecer el grado, de acuerdo entre el consenso de dos radiólogos, y el diagnóstico definitivo, emitido por un grupo de expertos. Adicionalmente, describir los hallazgos radiológicos donde el diagnóstico fue acertado. Tipo de estudio: estudio de concordancia. Lugar del estudio: Instituto Nacional de Cancerología (Bogotá). Pacientes y métodos: 45 pacientes con sospecha por imágenes de displasia fibrosa ósea y diagnóstico definitivo por correlación clínica, radiológica e histológica, se realizaron pruebas de concordancia para evaluar el desempeño clínico de los radiólogos y la frecuencia de los hallazgos en los casos acertados. Resultados: los diagnósticos diferenciales fueron osteomielitis, encondroma solitario, encondromatosis múltiple, osteoblastoma, quiste óseo solitario y fibroma no osificante. La coincidencia entre el diagnóstico radiológico y el diagnóstico definitivo fue considerada sustancial o muy buena (kappa 0,6353). Las cinco patologías donde no hubo acuerdo diagnóstico fueron: la mastocitosis ósea poliostótica, el granuloma reparativo de células gigantes, el fibroma cemento-osificante, el fibroma no osificante y la osteomielitis crónica. La presentación radiológica del granuloma reparativo de células gigantes y el fibroma cemento-osificante son indistinguibles de la displasia fibrosa ósea, por lo tanto, se hace necesaria la confirmación histológica


Asunto(s)
Displasia Fibrosa Ósea/clasificación , Displasia Fibrosa Ósea/diagnóstico , Displasia Fibrosa Ósea
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...